Literature DB >> 1370057

Inhibitors of angiogenesis.

M A Moses1, R Langer.   

Abstract

Angiogenesis, the formation of new capillaries, is essential to a number of important physiological events, both normal and pathological. Recently, increased attention has focused on the purification and characterization of inhibitors of this process, because of the potential therapeutic value of angiogenesis inhibitors in controlling such "angiogenic diseases" as proliferative retinopathy, solid tumors, rheumatoid arthritis, and neovascular glaucoma. We review the process of neovascularization and the assays that have been developed to study its inhibition in vivo and in vitro. We also discuss the properties of different angiogenesis inhibitors and examine the mechanisms by which such inhibitors could potentially intervene in the process of neovascularization.

Entities:  

Mesh:

Year:  1991        PMID: 1370057     DOI: 10.1038/nbt0791-630

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  19 in total

Review 1.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

Review 3.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

4.  Early embryonic angiogenesis in the chick area vasculosa.

Authors:  W E Allen; D J Wilson
Journal:  J Anat       Date:  1993-12       Impact factor: 2.610

5.  Embryonic chick muscle produces an FGF-like activity.

Authors:  D S Morris; S J Stock; J C McLachlan
Journal:  Experientia       Date:  1996-08-15

Review 6.  Molecular/cell engineering approach to autocrine ligand control of cell function.

Authors:  D A Lauffenburger; K E Forsten; B Will; H S Wiley
Journal:  Ann Biomed Eng       Date:  1995 May-Jun       Impact factor: 3.934

7.  A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice.

Authors:  I J Polakowski; M K Lewis; V R Muthukkaruppan; B Erdman; L Kubai; R Auerbach
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

Review 8.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

9.  Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK1 or interleukin-1 receptor antagonists.

Authors:  T P Fan; D E Hu; S Guard; G A Gresham; K J Watling
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

10.  Evaluation of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents.

Authors:  Vinod Kumar Sanna; Manu Jaggi; Vadlapudi Kumar; Anand C Burman
Journal:  Invest New Drugs       Date:  2009-05-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.